Conference Coverage

VIDEO: Cannabis further compromises cognitive function in some MS patients


 

AT THE CMSC ANNUAL MEETING

References

INDIANAPOLIS – Although an estimated 10%-20% of multiple sclerosis patients currently smoke cannabis for pain control or to alleviate symptoms, new research from Canada suggests that smoking the drug can worsen cognitive function in some patients with the disease.

“We already know that 40%-70% of people with MS already have cognitive problems,” Dr. Anthony Feinstein, professor of psychiatrist at the University of Toronto, said in a video interview at the annual meeting of the Consortium of Multiple Sclerosis Centers. “Some of the research that I’ve done shows that, in the presence of cannabis, these rates go up.”

Even so, he emphasized that patients should weigh such side effects against the benefits of use.

“I think it’s going to be an individual decision,” he said. “If it’s helping with pain, that’s good. Our data needs to be replicated by other groups.”

Dr. Feinstein disclosed that his work on MS and cannabis is funded by the Multiple Sclerosis Society of Canada.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

dbrunk@frontlinemedcom.com

On Twitter @dougbrunk

Recommended Reading

Online stem cell clinics lack adequate regulation, researchers charge
MDedge Psychiatry
Pseudobulbar affect: More common than you’d think
MDedge Psychiatry
AAN calls oral cannabinoids effective for MS pain, spasticity
MDedge Psychiatry
iPad app could change how MS is measured, treated
MDedge Psychiatry
VIDEO: Helping MS patients regain use of their limbs
MDedge Psychiatry
Alemtuzumab safety and efficacy persist at 4 years in relapsing-remitting multiple sclerosis
MDedge Psychiatry
Factors may identify high-risk patients with clinically isolated syndrome
MDedge Psychiatry
MS overrepresented in depression, bipolar; schizophrenia possibly protective
MDedge Psychiatry
FDA issues new pregnancy/lactation drug label standards
MDedge Psychiatry
FDA approves first generic version of MS drug glatiramer acetate
MDedge Psychiatry